论文部分内容阅读
局部小剂量溶栓的应用正逐渐增加,大多数是应用链激酶的经验,但新的药物,如重组体组织纤维蛋白溶酶原活化剂(rTPA)可能提供更有效的溶解作用,并减少合併症.作者复习了1974年至1988年间发表的19篇计1401例病人接受小剂量动脉内溶栓治疗的前瞻性研究资料,其中1224例病人为链激酶治疗,剂量5000～10000单位小时~(-1);177例病人应用rTPA,剂量0.25mg小时~(-1)～10mg小时~(-1).作者计算了上述治疗的卒中,大量出血、小量出血等合併症的发生率.
The use of local low-dose thrombolysis is gradually increasing, most of whom have experience with streptokinase, but new agents, such as recombinant tissue plasminogen activator (rTPA), may provide more effective lysis and reduce consolidation The authors reviewed 19 prospectively published data from 19 articles published between 1974 and 1988 in 1401 patients undergoing low-dose intra-arterial thrombolysis, 1224 of whom were treated with streptokinase at doses of 5,000 to 10,000 units- 1), and 177 patients received rTPA at a dose of 0.25 mg hour -1 to 10 mg hour -1. The authors calculated the incidence of complications such as stroke, mass bleeding and small amount of bleeding in the above treatment.